Loading
A phase 1/2 trial of ADG126, Pembrolizumab, Bevacizumab, Trifluridine/tipiracil and Fruquintinib in advanced solid tumours, run by Adagene Inc, now recruiting.
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05405595 by Adagene Inc, with 186 participants planned, started 2022-06-15 and due to reach its primary completion in 2026-10-31. Interventions recorded: ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab) and Standard of care (Fruquintinib).
Shares Bevacizumab, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares ADG126, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.